Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1392

Sort by

Sort Order Select

Journal Articles

Targeting the p-D-C: easy as C-D-1-2-3?

Naveen Pemmaraju

Blood (2021) 137 (10): 1277–1278.

https://doi.org/10.1182/blood.2020008745

Published: 2021

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Roger Belizaire, MD PhD, Sebastian Koochaki, BS, MS, Namrata Udeshi, PhD, Alexis Vedder, BS, Lei Sun, Monica Schenone, PhD, Steven Carr, PhD, Eric Padron, MD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 563.

https://doi.org/10.1182/blood-2019-122503

Published: 2019

Journal Articles

Gata2 Expression and Function in PML-RARA- driven Preleukemia and APL

Casey D.S. Katerndahl, PhD, Timothy J Ley, MD, Michelle A Cai, Timothy P Rooney, Jr., Sai Mukund Ramakrishnan, MS, Sridhar Nonavinkere Srivatsan, MS, Christopher A Miller, PhD

Blood (2019) 134 (Supplement_1): 534.

https://doi.org/10.1182/blood-2019-131883

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice

Yuanbin Song, MD, Liang Shan, PhD, Rana Gbyli, MS, Wei Liu, PhD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Ashley Qin, Amisha Patel, MS, Yimeng Gao, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, David Urbonas, Jonathan Alderman, PhD, Stephanie Halene, MD, Richard Flavell, PhD

Blood (2019) 134 (Supplement_1): 338.

https://doi.org/10.1182/blood-2019-130701

Published: 2019

Journal Articles

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Jie Zhou, Aibin Liang, PhD, Shaoguang Li, Wenjun Zhang, Jianfei FU, MD

Blood (2019) 134 (Supplement_1): 5394.

https://doi.org/10.1182/blood-2019-125434

Published: 2019

Journal Articles

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

Isabella Iasenza, Meaghan Boileau, BSc, Andrea Neumann, BSc., Héloïse Frison, MSc., Mark D. Minden, MD PhD, Isabelle Laverdiere, BPharm, MSc, PhD, Kolja Eppert, MSc, PhD

Blood (2019) 134 (Supplement_1): 5052.

https://doi.org/10.1182/blood-2019-125338

Published: 2019

Journal Articles

Leukemic Cell with a Novel Kinase Fusion Gene SPAG9-JAK2 Exhibits High Sensitivity to Ruxolitinib

Azusa Mayumi, MD, Toshihiro Tomii, MD, Toshihiko Imamura, MD PhD, Machiko Kawamura, MD, Hajime Hosoi, MD PhD

Blood (2019) 134 (Supplement_1): 5044.

https://doi.org/10.1182/blood-2019-126592

Published: 2019

Journal Articles

Hispanic Ethnicity Is Associated with Low End of Induction Absolute Lymphocyte Count in Pediatric Acute Lymphoblastic Leukemia

Adriana Saavedra-Simmons, Wanda LeJeune, M.Sc., Geraldine Aubert, PhD, Kellen Gandy, PhD, Lisa R. Hartman, MD, Jill Hartley, MSN, RN, Rodrigo Erana, MD, Juan C. Bernini, MD, Olga Taylor, MPH, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Karen R. Rabin, MD PhD, Maria Monica Monica Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 5197.

https://doi.org/10.1182/blood-2019-131222

Published: 2019

Journal Articles

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Gregor Eisenwort, MD PhD, Alexandra Keller, Michael Willmann, Irina Sadovnik, Greiner Georg, MD PhD, Karoline V. Gleixner, MD, Daniel Ivanov, MSc, Daniela Berger, Gabriele Stefanzl, Christiana Winding, DVM, Gregor Hoermann, Wolfgang R. Sperr, MD, Heinz Sill, MD, Peter Bettelheim, MD, Klaus Geissler, MD, Michael W. Deininger, Thomas Rülicke, Peter Valent, MD

Blood (2019) 134 (Supplement_1): 4223.

https://doi.org/10.1182/blood-2019-122530

Published: 2019

Journal Articles

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Sunil K Joshi, BA, William Bisson, PhD, Kristin Qian, Ariane Huang, Kevin Watanabe-Smith, PhD, Jeffrey W. Tyner, Monika Ashok Davare, PhD, Shannon K. McWeeney, PhD, Cristina E. Tognon, Brian J. Druker

Blood (2019) 134 (Supplement_1): 1256.

https://doi.org/10.1182/blood-2019-125908

Published: 2019

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Stephanie Berg, DO, Manuel O. Diaz, MD, Sucha Nand, MD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2969.

https://doi.org/10.1182/blood-2019-124805

Published: 2019

Journal Articles

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement

Mark Wunderlich, MS, Jing Chen, Eric O'Brien, BSc, Nicole Manning, Christina Sexton, Luke Byerly, John P Perentesis, Benjamin Mizukawa, James C Mulloy

Blood (2019) 134 (Supplement_1): 3766.

https://doi.org/10.1182/blood-2019-129225

Published: 2019

Journal Articles

The Clinical and Functional Relevance of the Transforming AKT E17K Mutation in T-ALL

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Izabela Mollova, BSc, Laura Graus, BSc, Frank L. Bos, PhD, Anne C. Rios, PhD, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 3804.

https://doi.org/10.1182/blood-2019-124669

Published: 2019

Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 4139.

https://doi.org/10.1182/blood-2019-127839

Published: 2019

Journal Articles

Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions

Noriaki Yoshida, MD PhD, Kay Shigemori, Samuel Y. Ng, MD PhD, Ajit Nirmal, PhD, Nicolas Donaldson, Nicolas Cordero, Kristen E. Stevenson, MS, Xia Bu, Mai Takeuchi, MD PhD, Koichi Ohshima, MD PhD, Akinori Yoda, PhD, David M Weinstock

Blood (2019) 134 (Supplement_1): 2760.

https://doi.org/10.1182/blood-2019-122525

Published: 2019

Journal Articles

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Yuichi Ishikawa, MD PhD, Koichi Saito, PhD, Naomi Kawashima, MD PhD, Michie Morimoto, Hidetoshi Murao, PhD, Daisuke Terada, Takeshi Yamaura, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2672.

https://doi.org/10.1182/blood-2019-124632

Published: 2019

NARROW

Targeting the p-D-C: easy as C-D-1-2-3?

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Gata2 Expression and Function in PML-RARA- driven Preleukemia and APL

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice

Activation of JAK2/STAT5 Pathway Reduces Expression Level of DNMT3a in MPN Cell Line

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

Leukemic Cell with a Novel Kinase Fusion Gene SPAG9-JAK2 Exhibits High Sensitivity to Ruxolitinib

Hispanic Ethnicity Is Associated with Low End of Induction Absolute Lymphocyte Count in Pediatric Acute Lymphoblastic Leukemia

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in Leukemia

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement

The Clinical and Functional Relevance of the Transforming AKT E17K Mutation in T-ALL

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only